Recent News

• 11.11.2025 - PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
• 11.10.2025 - PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
• 10.30.2025 - New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
• 10.29.2025 - PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
• 09.18.2025 - PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
• 09.02.2025 - PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.25.2025 - PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
• 08.13.2025 - PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

Recent Filings

• 11.10.2025 - EX-99.1 EX-99.1
• 11.10.2025 - 8-K Current report
• 10.29.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 8-K Current report
• 09.18.2025 - 8-K Current report
• 09.18.2025 - EX-99.1 EX-99.1
• 08.29.2025 - S-3 Registration statement under Securities Act of 1933
• 08.25.2025 - 8-K Current report
• 08.25.2025 - EX-99.1 EX-99.1
• 08.25.2025 - 8-K Current report